SHOCKWAVE MED INC (NASDAQ:SWAV) Stock, Quote.Headers.trade-ideas

Shockwave Medical

ShockWave Medical

Sarepta_Boston_232

News

Movers

SRPT

SWAV

Sarepta Therapeutics, Inc. (NASDAQ: SRPT) stock is trading higher on Thursday after it was announced the company will be added to the S&amp;P MidCap 400.

Why Sarepta Therapeutics Stock Is Rising Today

jnj johnson shutter

Biotech

Large Cap

Health Care

General

Johnson &amp; Johnson acquires Proteologix for $850 million, expanding its bispecific antibody portfolio for immune-mediated diseases.

Johnson &amp; Johnson To Acquire Early-Stage Eczema Treatment Developer Proteologix For $850M

Opinion

Federal Reserve

Markets

One of the best experiences I’ve had in my investment career was being partner and co portfolio manager with Raji Khabbaz. He’s a fantastic stock-picker and the two of us spent the  better part of a decade discussing and debating investment ideas.

Monthly Depth Report: The Blind Leading The Confused

SHOCKWAVE MED INC

<p><strong>David Goubert</strong> has resigned as president and CEO of <strong>Ayr Wellness Inc.</strong> (CSE:<a class="ticker" href="https://www.benzinga.com/stock/AYR#CSE">AYR</a>) (OTC:<a class="ticker" href="https://www.benzinga.com/stock/AYRWF#OTC">AYRWF</a>), a Miami-based cannabis multistate operator, after less than a <a href="https://www.benzinga.com/topic/ayr-wellness">year in the role. </a></p>
<p>Goubert, who joined the company as president in October of 2022 and took over as CEO in February 2023, is the latest in a series of executive departures at the company, MJBizDaily <a href="https://mjbizdaily.com/cannabis-operator-ayr-wellness-loses-ceo-david-goubert/">reported.</a></p>
<p><strong>See Also: <a href="https://www.benzinga.com/markets/cannabis/24/08/40222855/ayr-wellness-reports-qoq-drop-in-q2-revenue-gross-profit-but-plans-to-make-the-most-of-ohio-cann">AYR Wellness&#8217; Conditional Approval For Medical Marijuana Operations In Virginia, What It Means For Investors</a></strong></p>
<p>The resignation was announced alongside Ayr&#8217;s second-quarter earnings report, which revealed a slight dip in earnings and growing net losses. </p>
<p>Ayr's board of directors has initiated a search for a permanent CEO, while <strong>Steven Cohen</strong>, previously an external legal adviser, will serve as interim CEO.</p>
<h3 class="wp-block-heading">Are Leadership Changes Enough?</h3>
<p>In the second quarter of 2024, the company reported a slight decrease in revenue, down 0.6% from the previous quarter to $117.3 million. </p>
<p>While the MSO managed to reduce its overall expenses, net losses increased to $38 million, a significant jump from the $29 million reported a year earlier.</p>
<p>The company has been attempting to stabilize its financial footing amid these losses. As Goubert explained before his resignation, Ayr was focused on "laying the groundwork for Ayr's next phase of growth."</p>
<h3 class="wp-block-heading">Interim Leadership</h3>
<p>Cohen, who will assume the role of interim CEO, brings a legal and corporate governance background but lacks direct cannabis industry experience. He is a founding member of <strong>Blue Raven,</strong> a New York-based legal advisory firm specializing in strategic corporate advice and general counsel services.</p>
<p>Cohen's appointment follows another notable departure, <strong>Jonathan Sandelman</strong>, who stepped down as director and executive chair in July, marking the second high-profile exit within just a few months.</p>
<p><strong>Read Next:</strong></p>
<ul>
<li><a href="https://www.benzinga.com/markets/cannabis/24/08/40222855/ayr-wellness-reports-qoq-drop-in-q2-revenue-gross-profit-but-plans-to-make-the-most-of-ohio-cann">Ayr Wellness Reports QoQ Drop In Q2 Revenue &amp; Gross Profit But Plans To Make The Most Of Ohio Cannabis Sales</a></li>
</ul>
<p><em>Cover image made with AI.</em></p>


Cannabis

Movers & Shakers

Management

AYRWF

CSE:AYR

Cannabis Multi-State Operator Ayr Wellness Seeks New CEO After David Goubert's Departure: 'Next Phase Of Growth' Coming?

<p><strong>MillerKnoll, Inc. </strong>(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MLKN#NASDAQ">MLKN</a>) shares are trading lower after the company reported its first-quarter financial results after Thursday's closing bell. Here's a look at the <a href="https://www.benzinga.com/pressreleases/24/09/n40947407/millerknoll-inc-reports-first-quarter-fiscal-2025-results">details from the report. </a></p>
<p><strong>The Details:</strong> MillerKnoll reported quarterly earnings of 36 cents per share, which missed the analyst consensus estimate of 40 cents. Quarterly revenue of $861.50 million also missed the consensus estimate of $889.3 million and represents a 6.12% decrease from the same period last year.</p>
<ul>
<li>Orders in the first quarter were up 2.4% on a reported basis and up 3.5% organically from the prior year, led by Americas Contract growth of 5.2%.</li>
<li>Ending backlog of $758 million increased 9.2% from last year and 10.9% from the start of fiscal 2025.</li>
<li>Gross margin in the Global Retail segment improved by 160 basis points due to continued benefits from operational improvements.</li>
</ul>
<p>&#8220;While demand trends in our Retail segment continue to reflect the impact of a tepid housing market, the investments we have made in platform operational capabilities are not only driving significant margin improvements, but also position us to support profitable growth plans as the macro-economic backdrop improves. We believe our first quarter financial results demonstrate the advantage of our collective of brands, diverse business channels and global footprint,&#8221; the company wrote in a letter to shareholders. </p>
<p><strong>Read Next: </strong><a href="https://www.benzinga.com/fintech/24/09/40928342/what-happened-with-sofi-stock-today"><strong>What Happened With SoFi Stock Today?</strong></a></p>
<p><strong>Outlook:</strong> MillerKnoll sees second-quarter earnings of between 51 cents and 57 cents per share, versus the estimate of 61 cents, and second-quarter revenue in a range of $950 million to $990 million, versus the $948.12 million estimate. <br />BZ Wire</p>
<p><strong>MLKN Price Action:</strong> According to <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, MillerKnoll shares are down 2.62% after-hours at $26.75 at the time of publication Thursday. </p>
<p><strong>Read Also:</strong></p>
<ul>
<li><a href="https://www.benzinga.com/news/24/09/40923038/whats-going-on-with-carnival-stock"><strong>What&#8217;s Going On With Carnival Stock?</strong></a></li>
</ul>
<p><em>Photo: Shutterstock</em></p>


Earnings

MLKN

MillerKnoll Stock Dips After Q1 Results: Here's Why

<p><strong>Chewy Inc </strong>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CHWY#NYSE">CHWY</a>) shares are trading lower in Thursday&#8217;s after-hours session after the company announced a public offering by a selling stockholder and a <a href="https://www.benzinga.com/pressreleases/24/09/b40948271/chewy-inc-announces-public-offering-of-class-a-common-stock-by-selling-stockholder-and-concurrent-">concurrent share repurchase</a>.</p>
<p><strong>What Happened:</strong> After the market close, Chewy announced an underwritten offering of&nbsp;$500 million&nbsp;of its common stock by <strong>Buddy Chester Sub LLC</strong>, which is an entity affiliated with funds advised by Chewy&#8217;s largest shareholder <strong>BC Partners Advisors LP</strong>.</p>
<p>The selling stockholder expects to grant the underwriters a 30-day option to purchase up to an additional&nbsp;$75 million&nbsp;of Chewy common stock. The online pet retailer will not sell any shares in the offering or receive any proceeds. </p>
<p>Chewy also agreed to purchase $300 million worth of its common stock from the selling stockholder at a price equal to the price paid by the underwriters in the offering. The repurchased shares will be canceled and retired upon completion of the concurrent repurchase.</p>
<p>Chewy noted that its existing <a href="https://www.benzinga.com/news/earnings/24/05/39064898/pet-supply-focused-chewy-shares-gain-on-better-than-anticipated-q1-earnings-500m-buyback-plan">$500 million share repurchase program</a> will not be affected by this transaction. </p>
<p><strong>Don&#8217;t Miss: <a href="https://www.benzinga.com/news/earnings/24/09/40948046/fedex-q1-earnings-revenue-miss-eps-miss-lowered-guidance-challenging-quarter">FedEx Q1 Earnings: Revenue Miss, EPS Miss, Lowered Guidance — &#8216;Challenging Quarter&#8217;</a></strong></p>
<p><strong>CHWY Price Action:</strong> Chewy shares were down 3.09% in after hours, trading at $30.15 at the time of publication Thursday, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.</p>
<p><em>Photo: <a href="https://pixabay.com/users/huoadg5888-8934889/?utm_source=link-attribution&amp;utm_medium=referral&amp;utm_campaign=image&amp;utm_content=4415649">huoadg5888</a> from Pixabay.</em></p>


Offerings

Buybacks

After-Hours Center

CHWY

Chewy Stock Is Sliding After Hours: What's Going On?

<p>Telsey Advisory Group  analyst Joseph Feldman   maintains Target (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TGT#NYSE">TGT</a>) with a Outperform and maintains $195 price target.</p>


Price Target

Analyst Ratings

Telsey Advisory Group Maintains Outperform on Target, Maintains $195 Price Target

<p><strong>Lennar Corp </strong>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LEN#NYSE">LEN</a>) reported its third-quarter financial results after Thursday's closing bell. Here's a look at the <a href="https://www.benzinga.com/pressreleases/24/09/n40948079/lennar-reports-third-quarter-2024-results">details from the report. </a></p>
<p><strong>The Details:</strong> Lennar reported quarterly earnings of $3.90 per share, which beat the analyst consensus estimate of $3.63 by 7.44%. Quarterly revenue clocked in at $9.416 billion, beating the consensus estimate of $9.164 billion and representing a 7.86% increase over the same period last year.</p>
<ul>
<li>New orders increased 5% to 20,587 homes.</li>
<li>Lennar reported a backlog of 16,944 homes with a dollar value of $7.7 billion.</li>
<li>Deliveries increased 16% to 21,516 homes. </li>
<li>Lennar reported homebuilding operating earnings of $1.5 billion with gross margin on home sales of 22.5%.</li>
<li>Average home price was $422,000 in the third quarter,</li>
</ul>
<p>&#8220;We are pleased to report another solid quarter backed by an economic environment that remains very constructive for homebuilders. Employment was strong, housing supply remained chronically short due to production deficits of over a decade and demand was solid driven by strong household formation,&#8221; said <strong>Stuart Miller</strong>, executive chairman and Co-CEO of Lennar.</p>
<p>&#8220;Although affordability continued to be tested during the quarter, purchasers remained responsive to increased sales incentives, resulting in a 16% increase in our deliveries and a 5% increase in our new orders year over year,&#8221; Miller added.</p>
<p><strong>Read Next: </strong><a href="https://www.benzinga.com/fintech/24/09/40928342/what-happened-with-sofi-stock-today"><strong>What Happened With SoFi Stock Today?</strong></a></p>
<p><strong>Outlook:</strong> Lennar sees fourth-quarter new orders in a range of 19,000 to 19,300 and deliveries between 22,500 and 23,000. The company expects the average sales price to be approximately $425,000.</p>
<p><strong>What Else:</strong> The company will host a conference call at 11 a.m. ET Friday to discuss the results. BofA Securities analyst <strong>Rafe Jadrosich</strong> maintained Lennar with a Neutral rating and raised the price target from $171 to $190 before the print on Thursday.</p>
<p><strong>LEN Price Action:</strong> According to <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, Lennar shares are down 3.36% in extended trading at $185.99 after gaining 2.13% in Thursday&#8217;s regular session.</p>
<p><strong>Read Also:</strong></p>
<ul>
<li><a href="https://www.benzinga.com/news/24/09/40923038/whats-going-on-with-carnival-stock"><strong>What&#8217;s Going On With Carnival Stock?</strong></a></li>
</ul>
<p><em>Photo: Shutterstock</em></p>


Homebuilder Lennar Reports Better-Than-Expected Q3 Results: Details

<p>West Fraser Timber Co. Ltd. ("West Fraser" or the "Company") (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WFG#NYSE">WFG</a>) announced today that it will indefinitely curtail its sawmill in Lake Butler, Florida by the end of this month. Today's decision is the result of high fiber costs and soft lumber markets.</p>
<p>The indefinite curtailment of Lake Butler Sawmill will impact approximately 130 employees and reduce West Fraser's U.S. lumber capacity by approximately 110 million board feet. West Fraser expects to mitigate the impact on affected employees by providing work opportunities at other company operations.</p>
<p>High fiber costs at Lake Butler and the current low-price commodity environment have impaired the ability to profitably operate the mill. The indefinite curtailment of Lake Butler sawmill better aligns our U.S. lumber capacity with demand.</p>
<p>West Fraser anticipates taking an impairment charge in the third quarter of 2024 associated with the announcement.</p>


West Fraser Timber Co. Announces It Will Indefinitely Curtail Its Sawmill In Lake Butler, Florida By The End Of This Month, As A Result Of High Fiber Costs And Soft Lumber Markets

<p><strong>Toyota Tsusho Memorandum of Understanding</strong><br /><br />Arcadium Lithium announced the recent signing of a Memorandum of Understanding (MoU) with its long-time partner Toyota Tsusho Corporation (TTC), a key initial step in providing greater flexibility for Arcadium Lithium to optimize its global integrated operating network and to contribute its production expertise to Naraha.&nbsp; This includes using technical grade lithium carbonate produced at Olaroz to feed the Company's existing downstream lithium hydroxide network, thus allowing more battery grade lithium carbonate produced at Fénix to be sold directly to customers.&nbsp; This is expected to have a positive impact on the Company's earnings and to be achievable as early as 2026.</p>


Contracts

ALTM

Arcadium Lithium Announced The Recent Signing Of A MoU With Its Long-Time Partner Toyota Tsusho Corporation To Optimize Its Global Integrated Operating Network And To Contribute Its Production Expertise To Naraha, Expected To Have A Positive Impact On The Co's Earnings And To Be Achievable As Early As 2026

<ul>
<li>Underscores unique position as a vertically integrated, diversified global producer of lithium chemicals with low-cost and high-quality assets</li>
<li>Details ongoing expansion programs expected to more than double total sales volumes by 2028 across multiple products and regions</li>
<li>Outlines path to Adjusted EBITDA1 of $1.3 billion by 2028 supported by strong and flexible balance sheet with peak net leverage of 2.1x1,2</li>
<li>Reaffirms significant expansion potential of one of the largest and most diverse resource bases in the industry</li>
<li>Accelerating plan to deliver $125 million of merger-related cost savings roughly two years ahead of initial target</li>
<li>Executed Memorandum of Understanding (MoU) with Toyota Tsusho in key step to unlocking further synergies</li>
</ul>
<p>Arcadium Lithium plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALTM#NYSE">ALTM</a>, ASX: LTM, ", Arcadium Lithium", &amp;nbsp, or the ", Company", )))), a leading global lithium chemicals producer, today provided a number of strategic updates at its inaugural 2024 Investor Day. &nbsp;During the event, the Company reviewed its operating, commercial and growth strategies while reinforcing its commitment to sustainability leadership.&nbsp; The Company also discussed its plans for disciplined volume expansion and provided a long-term financial view.</p>


Guidance

Events

Arcadium Lithium's 2024 Investor Day Highlights Company's Strategic Vision And Pathway To Significant Growth; Sees Adjusted EBITDA Of $1.3B By 2028; Accelerating Plan To Deliver $125M Of Merger-Related Cost Savings Roughly 2-Years Ahead Of Initial Target

<p>Ratings for QuidelOrtho (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QDEL#NASDAQ">QDEL</a>) were provided by 4 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.</p>
<p>Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>Analysts have set 12-month price targets for QuidelOrtho, revealing an average target of $57.25, a high estimate of $61.00, and a low estimate of $50.00. Surpassing the previous average price target of $51.00, the current average has increased by 12.25%.</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1726779707_0.png" alt="price target chart" /></p>
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
<p>The standing of QuidelOrtho among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>John Sourbeer</td>
<td>UBS</td>
<td>Raises</td>
<td>Neutral</td>
<td>$50.00</td>
<td>$42.00</td>
</tr>
<tr>
<td>Alexander Nowak</td>
<td>Craig-Hallum</td>
<td>Raises</td>
<td>Buy</td>
<td>$57.00</td>
<td>$40.00</td>
</tr>
<tr>
<td>Conor McNamara</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$61.00</td>
<td>$61.00</td>
</tr>
<tr>
<td>Conor McNamara</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$61.00</td>
<td>$61.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to QuidelOrtho. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of QuidelOrtho compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
<p>Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of QuidelOrtho's market standing. Stay informed and make data-driven decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/QDEL/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on QuidelOrtho analyst ratings.</strong></a></p>
<h2>Unveiling the Story Behind QuidelOrtho</h2>
<p>QuidelOrtho Corp is engaged in the development, manufacturing, and marketing of rapid diagnostic testing solutions. The company is engaged in immunoassay and molecular testing, clinical chemistry and transfusion medicine which helps clinicians and patients to make decisions across the globe. Geographically the company has its presence in North America, EMEA, China and Other countries. It generates majority if the revenue from North America.</p>
<h3>QuidelOrtho's Financial Performance</h3>
<p><strong>Market Capitalization Analysis:</strong> Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.</p>
<p><strong>Negative Revenue Trend:</strong> Examining QuidelOrtho's financials over 3 months reveals challenges. As of 30 June, 2024, the company experienced a decline of approximately <strong>-4.22%</strong> in revenue growth, reflecting a decrease in top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.</p>
<p><strong>Net Margin:</strong> QuidelOrtho's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of <strong>-23.19%,</strong> the company may encounter challenges in effective cost control.</p>
<p><strong>Return on Equity (ROE):</strong> QuidelOrtho's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of <strong>-4.56%,</strong> the company showcases efficient use of equity capital and strong financial health.</p>
<p><strong>Return on Assets (ROA):</strong> QuidelOrtho's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of <strong>-2.21%,</strong> the company may encounter challenges in delivering satisfactory returns from its assets.</p>
<p><strong>Debt Management:</strong> The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at <strong>0.87</strong>.</p>
<h2>How Are Analyst Ratings Determined?</h2>
<p>Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.</p>
<p>Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


QDEL

Cracking The Code: Understanding Analyst Reviews For QuidelOrtho

<p>4 analysts have expressed a variety of opinions on Hain Celestial Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HAIN#NASDAQ">HAIN</a>) over the past quarter, offering a diverse set of opinions from bullish to bearish.</p>
<p>The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>Insights from analysts' 12-month price targets are revealed, presenting an average target of $8.5, a high estimate of $9.00, and a low estimate of $8.00. Witnessing a positive shift, the current average has risen by 9.68% from the previous average price target of $7.75.</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1726779681_0.png" alt="price target chart" /></p>
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
<p>The standing of Hain Celestial Group among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Michael Lavery</td>
<td>Piper Sandler</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$8.00</td>
<td>$8.00</td>
</tr>
<tr>
<td>Andrew Lazar</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$9.00</td>
<td>$7.00</td>
</tr>
<tr>
<td>Brian Holland</td>
<td>DA Davidson</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$8.00</td>
<td>$8.00</td>
</tr>
<tr>
<td>Matthew Smith</td>
<td>Stifel</td>
<td>Raises</td>
<td>Hold</td>
<td>$9.00</td>
<td>$8.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Hain Celestial Group. This offers insight into analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Hain Celestial Group compared to the broader market.</li>
<li><strong>Price Targets:</strong> Gaining insights, analysts provide estimates for the future value of Hain Celestial Group's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>Capture valuable insights into Hain Celestial Group's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/HAIN/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Hain Celestial Group analyst ratings.</strong></a></p>
<p>If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.</p>
<h2>Unveiling the Story Behind Hain Celestial Group</h2>
<p>The Hain Celestial Group Inc is a health and wellness company. It makes natural and organic food and personal-care products. The company offers products across various categories such as snacks, baby &amp; kids food, beverages, meal preparation, and personal care through brands like Garden Veggie Snacks, Terra chips, Garden of Eatin snacks, Hartley's Jelly, and Celestial Seasonings teas among others. It operates under two reportable segments; North America and International. The majority of its revenue is derived from the North America segment which represents the sale of its products in the United States and Canada. The International segment includes the sale of its products in the United Kingdom and the Western European region.</p>
<h3>Unraveling the Financial Story of Hain Celestial Group</h3>
<p><strong>Market Capitalization Analysis:</strong> Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.</p>
<p><strong>Revenue Growth:</strong> Hain Celestial Group's revenue growth over a period of 3 months has faced challenges. As of 30 June, 2024, the company experienced a revenue decline of approximately <strong>-6.48%</strong>. This indicates a decrease in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Consumer Staples sector.</p>
<p><strong>Net Margin:</strong> Hain Celestial Group's net margin excels beyond industry benchmarks, reaching <strong>-0.7%</strong>. This signifies efficient cost management and strong financial health.</p>
<p><strong>Return on Equity (ROE):</strong> Hain Celestial Group's ROE stands out, surpassing industry averages. With an impressive ROE of <strong>-0.31%</strong>, the company demonstrates effective use of equity capital and strong financial performance.</p>
<p><strong>Return on Assets (ROA):</strong> Hain Celestial Group's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of <strong>-0.14%,</strong> the company may face hurdles in achieving optimal financial returns.</p>
<p><strong>Debt Management:</strong> The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at <strong>0.89</strong>.</p>
<h2>The Basics of Analyst Ratings</h2>
<p>Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.</p>
<p>Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


HAIN

Demystifying Hain Celestial Group: Insights From 4 Analyst Reviews

<p>In the latest quarter, 4 analysts provided ratings for Harley-Davidson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HOG#NYSE">HOG</a>), showcasing a mix of bullish and bearish perspectives.</p>
<p>In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>Insights from analysts' 12-month price targets are revealed, presenting an average target of $40.75, a high estimate of $44.00, and a low estimate of $39.00. Witnessing a positive shift, the current average has risen by 4.49% from the previous average price target of $39.00.</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1726779669_0.png" alt="price target chart" /></p>
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
<p>A clear picture of Harley-Davidson's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>James Hardiman</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Neutral</td>
<td>$39.00</td>
<td>$37.00</td>
</tr>
<tr>
<td>Robin Farley</td>
<td>UBS</td>
<td>Raises</td>
<td>Neutral</td>
<td>$40.00</td>
<td>$39.00</td>
</tr>
<tr>
<td>Craig Kennison</td>
<td>Baird</td>
<td>Raises</td>
<td>Outperform</td>
<td>$44.00</td>
<td>$40.00</td>
</tr>
<tr>
<td>Craig Kennison</td>
<td>Baird</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$40.00</td>
<td>$40.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Harley-Davidson. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Harley-Davidson compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts navigate through adjustments in price targets, providing estimates for Harley-Davidson's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
<p>To gain a panoramic view of Harley-Davidson's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/HOG/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Harley-Davidson analyst ratings.</strong></a></p>
<h2>All You Need to Know About Harley-Davidson</h2>
<p>Harley-Davidson is a leading global manufacturer of heavyweight motorcycles across the custom, cruising, and touring segments, as well as related merchandise, parts, and accessories. In recent years, the firm has expanded into the adventure touring market with its Pan America model and into electric with the LiveWire brand. Its captive finance arm, Harley-Davidson Financial Services, provides wholesale financing to dealers and retail financing and insurance brokerage services to customers. Harley captured around 38% of the heavyweight domestic market in 2023.</p>
<h3>A Deep Dive into Harley-Davidson's Financials</h3>
<p><strong>Market Capitalization:</strong> Exceeding industry standards, the company's market capitalization places it above industry average in size relative to peers. This emphasizes its significant scale and robust market position.</p>
<p><strong>Revenue Growth:</strong> Harley-Davidson's revenue growth over a period of 3 months has been noteworthy. As of 30 June, 2024, the company achieved a revenue growth rate of approximately <strong>11.99%</strong>. This indicates a substantial increase in the company's top-line earnings. When compared to others in the Consumer Discretionary sector, the company faces challenges, achieving a growth rate lower than the average among peers.</p>
<p><strong>Net Margin:</strong> Harley-Davidson's net margin is impressive, surpassing industry averages. With a net margin of <strong>13.48%,</strong> the company demonstrates strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of <strong>6.44%,</strong> the company showcases effective utilization of equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> Harley-Davidson's ROA excels beyond industry benchmarks, reaching <strong>1.74%</strong>. This signifies efficient management of assets and strong financial health.</p>
<p><strong>Debt Management:</strong> With a high debt-to-equity ratio of <strong>2.19</strong>, Harley-Davidson faces challenges in effectively managing its debt levels, indicating potential financial strain.</p>
<h2>The Significance of Analyst Ratings Explained</h2>
<p>Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. </p>
<p>Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


The Analyst Verdict: Harley-Davidson In The Eyes Of 4 Experts

<p>During the last three months, 7 analysts shared their evaluations of Driven Brands Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DRVN#NASDAQ">DRVN</a>), revealing diverse outlooks from bullish to bearish.</p>
<p>Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>Analysts have recently evaluated Driven Brands Hldgs and provided 12-month price targets. The average target is $17.29, accompanied by a high estimate of $20.00 and a low estimate of $14.00. This current average reflects an increase of 5.88% from the previous average price target of $16.33. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1726779659_0.png" alt="price target chart" /></p>
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
<p>In examining recent analyst actions, we gain insights into how financial experts perceive Driven Brands Hldgs. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Brian McNamara</td>
<td>Canaccord Genuity</td>
<td>Raises</td>
<td>Buy</td>
<td>$20.00</td>
<td>$19.00</td>
</tr>
<tr>
<td>John Lawrence</td>
<td>Benchmark</td>
<td>Maintains</td>
<td>Buy</td>
<td>$20.00</td>
<td>$20.00</td>
</tr>
<tr>
<td>Steven Shemesh</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$16.00</td>
<td>$14.00</td>
</tr>
<tr>
<td>Peter Benedict</td>
<td>Baird</td>
<td>Raises</td>
<td>Outperform</td>
<td>$18.00</td>
<td>$17.00</td>
</tr>
<tr>
<td>Peter Keith</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$17.00</td>
<td>$14.00</td>
</tr>
<tr>
<td>Kate McShane</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Neutral</td>
<td>$16.00</td>
<td>$14.00</td>
</tr>
<tr>
<td>Tristan Thomas-Martin</td>
<td>BMO Capital</td>
<td>Announces</td>
<td>Market Perform</td>
<td>$14.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Driven Brands Hldgs. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Driven Brands Hldgs compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts navigate through adjustments in price targets, providing estimates for Driven Brands Hldgs's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
<p>Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Driven Brands Hldgs's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/DRVN/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Driven Brands Hldgs analyst ratings.</strong></a></p>
<h2>Get to Know Driven Brands Hldgs Better</h2>
<p>Driven Brands Holdings Inc is an automotive services company in North America. Its platform provides high-quality services to an extensive range of retail and commercial customers. The company provides an extensive range of core consumer and commercial automotive needs, including paint, collision, glass, and repair services, as well as a variety of high-frequency services, such as oil changes and car washes.</p>
<h3>Driven Brands Hldgs: Financial Performance Dissected</h3>
<p><strong>Market Capitalization Analysis:</strong> Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.</p>
<p><strong>Revenue Growth:</strong> Driven Brands Hldgs's remarkable performance in 3 months is evident. As of 30 June, 2024, the company achieved an impressive revenue growth rate of <strong>0.78%</strong>. This signifies a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Industrials sector.</p>
<p><strong>Net Margin:</strong> The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of <strong>4.93%,</strong> the company may need to address challenges in effective cost control.</p>
<p><strong>Return on Equity (ROE):</strong> The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of <strong>3.26%,</strong> the company may need to address challenges in generating satisfactory returns for shareholders.</p>
<p><strong>Return on Assets (ROA):</strong> Driven Brands Hldgs's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of <strong>0.51%,</strong> the company may face hurdles in achieving optimal financial performance.</p>
<p><strong>Debt Management:</strong> The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of <strong>4.46</strong>, caution is advised due to increased financial risk.</p>
<h2>What Are Analyst Ratings?</h2>
<p>Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.</p>
<p>Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.</p>
<p>If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


DRVN

Forecasting The Future: 7 Analyst Projections For Driven Brands Hldgs

<p>Ratings for Elanco Animal Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ELAN#NYSE">ELAN</a>) were provided by 4 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.</p>
<p>The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $18.0, along with a high estimate of $21.00 and a low estimate of $15.00. Highlighting a 8.86% decrease, the current average has fallen from the previous average price target of $19.75. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1726779650_0.png" alt="price target chart" /></p>
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
<p>The standing of Elanco Animal Health among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jonathan Block</td>
<td>Stifel</td>
<td>Maintains</td>
<td>Buy</td>
<td>$20.00</td>
<td>$20.00</td>
</tr>
<tr>
<td>Erin Wright</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$15.00</td>
<td>$17.00</td>
</tr>
<tr>
<td>David Westenberg</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$16.00</td>
<td>$19.00</td>
</tr>
<tr>
<td>Balaji Prasad</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$21.00</td>
<td>$23.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Elanco Animal Health. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Elanco Animal Health compared to the broader market.</li>
<li><strong>Price Targets:</strong> Understanding forecasts, analysts offer estimates for Elanco Animal Health's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
<p>Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Elanco Animal Health's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/ELAN/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Elanco Animal Health analyst ratings.</strong></a></p>
<h2>All You Need to Know About Elanco Animal Health</h2>
<p>Elanco Animal Health Inc is an animal health company that is engaged in innovating, developing, manufacturing, and marketing products for companion and food animals. Geographically, the company's operations are conducted globally and sell its products in over 90 countries. It offers a range of food animal products used in cattle, sheep, goats, and swine production. The company's product portfolio of approximately 200 brands.</p>
<h3>Elanco Animal Health's Financial Performance</h3>
<p><strong>Market Capitalization Analysis:</strong> The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.</p>
<p><strong>Revenue Growth:</strong> Elanco Animal Health's revenue growth over a period of 3 months has been noteworthy. As of 30 June, 2024, the company achieved a revenue growth rate of approximately <strong>12.02%</strong>. This indicates a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.</p>
<p><strong>Net Margin:</strong> Elanco Animal Health's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of <strong>-4.22%,</strong> the company may encounter challenges in effective cost control.</p>
<p><strong>Return on Equity (ROE):</strong> Elanco Animal Health's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of <strong>-0.83%,</strong> the company may face hurdles in achieving optimal financial returns.</p>
<p><strong>Return on Assets (ROA):</strong> Elanco Animal Health's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of <strong>-0.36%,</strong> the company may face hurdles in achieving optimal financial returns.</p>
<p><strong>Debt Management:</strong> Elanco Animal Health's debt-to-equity ratio is below the industry average at <strong>0.96</strong>, reflecting a lower dependency on debt financing and a more conservative financial approach.</p>
<h2>Analyst Ratings: Simplified</h2>
<p>Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. </p>
<p>Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.</p>
<p>If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


ELAN

Demystifying Elanco Animal Health: Insights From 4 Analyst Reviews

<p>Providing a diverse range of perspectives from bullish to bearish, 8 analysts have published ratings on MP Materials (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MP#NYSE">MP</a>) in the last three months.</p>
<p>In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>In the assessment of 12-month price targets, analysts unveil insights for MP Materials, presenting an average target of $19.12, a high estimate of $30.00, and a low estimate of $12.50. This current average represents a 5.77% decrease from the previous average price target of $20.29. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1726779624_0.png" alt="price target chart" /></p>
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
<p>A comprehensive examination of how financial experts perceive MP Materials is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Carlos De Alba</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$16.00</td>
<td>$13.50</td>
</tr>
<tr>
<td>George Gianarikas</td>
<td>Canaccord Genuity</td>
<td>Lowers</td>
<td>Buy</td>
<td>$19.00</td>
<td>$20.00</td>
</tr>
<tr>
<td>Corinne Blanchard</td>
<td>Deutsche Bank</td>
<td>Lowers</td>
<td>Hold</td>
<td>$12.50</td>
<td>$13.50</td>
</tr>
<tr>
<td>Subash Chandra</td>
<td>Benchmark</td>
<td>Maintains</td>
<td>Buy</td>
<td>$30.00</td>
<td>$30.00</td>
</tr>
<tr>
<td>Bill Peterson</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$15.00</td>
<td>$16.00</td>
</tr>
<tr>
<td>Ben Kallo</td>
<td>Baird</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$20.00</td>
<td>$24.00</td>
</tr>
<tr>
<td>Greg Jones</td>
<td>BMO Capital</td>
<td>Announces</td>
<td>Market Perform</td>
<td>$16.50</td>
<td>-</td>
</tr>
<tr>
<td>Lawson Winder</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$24.00</td>
<td>$25.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to MP Materials. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of MP Materials compared to the broader market.</li>
<li><strong>Price Targets:</strong> Understanding forecasts, analysts offer estimates for MP Materials's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
<p>Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into MP Materials's market standing. Stay informed and make well-considered decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/MP/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on MP Materials analyst ratings.</strong></a></p>
<h2>About MP Materials</h2>
<p>MP Materials Corp is the producer of rare earth materials in the Western Hemisphere. The company owns and operates the Mountain Pass Rare Earth Mine and Processing Facility, the only rare earth mining and processing site of scale in North America.</p>
<h3>Unraveling the Financial Story of MP Materials</h3>
<p><strong>Market Capitalization Analysis:</strong> With a profound presence, the company's market capitalization is above industry averages. This reflects substantial size and strong market recognition.</p>
<p><strong>Decline in Revenue:</strong> Over the 3 months period, MP Materials faced challenges, resulting in a decline of approximately <strong>-51.18%</strong> in revenue growth as of 30 June, 2024. This signifies a reduction in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Materials sector.</p>
<p><strong>Net Margin:</strong> MP Materials's net margin is impressive, surpassing industry averages. With a net margin of <strong>-108.95%,</strong> the company demonstrates strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> MP Materials's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of <strong>-3.03%,</strong> the company may face hurdles in achieving optimal financial returns.</p>
<p><strong>Return on Assets (ROA):</strong> MP Materials's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of <strong>-1.44%,</strong> the company may encounter challenges in delivering satisfactory returns from its assets.</p>
<p><strong>Debt Management:</strong> MP Materials's debt-to-equity ratio is notably higher than the industry average. With a ratio of <b>0.85</b>, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.</p>
<h2>The Basics of Analyst Ratings</h2>
<p>Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.</p>
<p>Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.</p>
<p>Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


The Analyst Landscape: 8 Takes On MP Materials

<p>Diamondback Energy, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FANG#NASDAQ">FANG</a>) ("Diamondback") announced today the launch of an underwritten public offering of 11,270,000 shares of its common stock by certain Legacy Endeavor Stockholders (the "Selling Stockholders"), subject to market and other conditions (the "Secondary Offering"). Diamondback will not receive any proceeds from the sale of the shares by the Selling Stockholders. The Selling Stockholders have also granted the underwriters a 30-day option to purchase up to an additional 1,390,500 shares of common stock.<br /><br />&nbsp;</p>
<p>In addition, Diamondback has authorized the purchase from the underwriters of 2,000,000 shares of common stock offered in the Secondary Offering (the "Share Repurchase"). The Share Repurchase is part of the Diamondback's existing share repurchase program. Diamondback intends to fund the Share Repurchase from existing cash on hand. The underwriters will not receive any compensation for the shares being repurchased by Diamondback in the Share Repurchase.</p>
<p>Evercore ISI, Citigroup and J.P. Morgan are acting as joint book-running managers for the Secondary Offering.</p>


FANG

Diamondback Energy Announces Launch Of Secondary Common Stock Offering Of 11.27M Shares Of Common Stock; Diamondback Has Authorized The Purchase From The Underwriters Of 2M Shares Of Common Stock Offered In The Secondary Offering As Part Of Its Existing Repurchase Program

<p>After a bullish session on Thursday, with both the S&amp;P 500 and the Dow Jones hitting record highs, spurred by increased risk appetite following a bold 0.5% rate cut by the Federal Reserve, traders are gearing up for a volatile <a href="https://www.benzinga.com/markets/cryptocurrency/24/09/40944143/wall-street-breaks-records-chipmakers-rally-tesla-hits-2-month-high-as-fed-cut-drives-risk">end to the week.</a></p>
<p>Friday marks a notorious &#8220;Triple Witching&#8221; day, when stock index futures, stock index options and individual stock options expire simultaneously — a convergence that historically stirs market turbulence.</p>
<p>Goldman Sachs estimates than more than $4.5 trillion in notional options exposure will expire on Friday, including $605 billion in single-stock options.  </p>
<p>According to Bloomberg, using estimates from derivatives analytical firm Asym 500, the overall notional options expiring Friday reach $5.1 trillion when including options tied to ETFs.</p>
<p>&#8220;This Friday will be the largest September-options expiration on record, driven by elevated index and ETF options volumes,&#8221; wrote Goldman Sachs analyst <strong>John Marshall</strong>. </p>
<p>While the September expiration will set a new record, it&#8217;s expected to be smaller than the previous quarterly expirations of 2024.</p>
<h3 class="wp-block-heading">A Record-Breaking Expiration Day</h3>
<p>Goldman Sachs highlighted that average daily index and ETF options volumes have reached a new high this quarter. In contrast, single-stock options trading has seen a decline. </p>
<p>The sheer magnitude of options expiring Friday could trigger a wave of volatility as traders scramble to adjust their position, and the Federal Reserve&#8217;s recent rate cut might not be enough to temper the storm.</p>
<p>Could this triple witching day spoil the market rally ignited by the Fed?</p>
<h3 class="wp-block-heading">What Is &#8216;Triple Witching&#8217;? How Did Markets Previously Perform? </h3>
<p>Triple witching refers to the simultaneous expiration of three types of derivative contracts — stock index futures, stock index options and single-stock options — on the same day, occurring quarterly on the third Friday of March, June, September and December.</p>
<p>This convergence can lead to heightened market volatility as traders close, roll over or offset their expiring contracts, often resulting in unusual price movements and increased trading volumes.</p>
<p>Looking back at the last three triple witching events, the S&amp;P 500, tracked by the <strong>SPDR S&amp;P 500 ETF Trust</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>), has struggled during these high-stakes trading days.</p>
<ul>
<li><strong>June 21, 2024:</strong> The S&amp;P 500 dropped 0.5%.</li>
<li><strong>March 15, 2024:</strong> The index fell by 1%.</li>
<li><strong>Dec. 15, 2023:</strong> The S&amp;P 500 declined 0.6%.</li>
</ul>
<p>Tech stocks, represented by the<strong> Invesco QQQ Trust</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>), underperformed in the last two triple witching occasions, falling 0.8% in June and 1.2% in March, while surging 0.5% in December 2023. </p>
<h3 class="wp-block-heading">Goldman Sachs Recommends VIX Calls Ahead of Volatility Spike</h3>
<p>September is historically the worst month for stock market performance.</p>
<p>According to <strong>Ryan Detrick</strong>, chief market strategist at Carson Group, the last two weeks of September are the worst period for stocks during the year, as the expert showed in a post on social media platform X.</p>
<p><figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"><br />
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true"><p lang="en" dir="ltr">You are here.<br /><br />The worst two weeks of the year for stocks. <a href="https://t.co/kXDg0lXKOX">pic.twitter.com/kXDg0lXKOX</a></p>
<p>&mdash; Ryan Detrick, CMT (@RyanDetrick) <a href="https://twitter.com/RyanDetrick/status/1835859506221461664?ref_src=twsrc%5Etfw">September 17, 2024</a></p></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
<p></p></figure></p>
<p>The CBOE Volatility Index (VIX), often referred to as the market&#8217;s fear gauge, has dropped significantly since its spike in August.</p>
<p>The index is sitting at 17, well below its multiyear average, and Goldman Sachs sees the VIX on the rise as we enter the seasonally volatile period.</p>
<p>Goldman Sachs&#8217; economic model estimates that, given macroeconomic conditions, the VIX should be at 24.5, suggesting the current low volatility may not last much longer.</p>
<p>The investment bank issued a recommendation for investors to hedge their portfolios using VIX calls. Specifically, Goldman Sachs analysts advise buying CBOE Volatility Index (VIX) November calls at a strike price of 18.</p>
<p><strong>Read Next:</strong></p>
<ul>
<li><strong><a href="https://www.benzinga.com/trading-ideas/technicals/24/09/40942814/boeing-braces-for-turbulence-as-strikes-furloughs-send-stock-sliding-bearish-signals-pre">Boeing Braces For Turbulence As Strikes, Furloughs Send Stock Sliding, Bearish Signals Prevail</a></strong></li>
</ul>
<p><em>Photo via Shutterstock. </em></p>


Analyst Color

Equities

Broad U.S. Equity ETFs

Previews

Options

Tech

ETFs

Traders Brace For Friday Volatility As Over $5 Trillion In Options Expire: Could 'Triple Witching' Spoil Fed's Rally?

<p><strong>Nike Inc</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NKE#NYSE">NKE</a>) shares are jumping in Thursday&#8217;s after-hours session after the company <a href="https://www.benzinga.com/pressreleases/24/09/b40947704/nike-inc-board-of-directors-announces-long-time-nike-veteran-elliott-hill-to-return-as-president-a">announced a CEO transition</a>.</p>
<p><strong>What Happened:</strong> After the market close on Thursday, Nike announced that longtime Nike veteran <strong>Elliott Hill</strong> will become president and CEO of Nike, effective Oct. 14. Hill will also become a director on the board and a member of the executive committee.</p>
<p>The board and<strong> John Donahoe</strong> made the decision that Donahoe will retire from his role as president and CEO of Nike, effective Oct. 13. The exiting CEO will remain an advisor to the company through Jan. 31, 2025, to ensure a smooth transition.</p>
<p>&#8220;Given our needs for the future, the past performance of the business, and after conducting a thoughtful succession process, the Board concluded it was clear Elliott&#8217;s global expertise, leadership style, and deep understanding of our industry and partners, paired with his passion for sport, our brands, products, consumers, athletes, and employees, make him the right person to lead Nike&#8217;s next stage of growth,&#8221; said <strong>Mark Parker</strong>, executive chairman of Nike.</p>
<p>&#8220;Personally, I have worked with Elliott for more than 30 years and I look forward to supporting him and his senior management team as they seize the opportunities ahead.&#8221;</p>
<p><strong>Related Link: <a href="https://www.benzinga.com/news/24/09/40941277/whats-going-on-with-nike-stock">What&#8217;s Going On With Nike Stock?</a></strong></p>
<p>Throughout his career at Nike, Hill held senior leadership positions across Europe and North America before retiring in 2020. Before his retirement, he was president of the company&#8217;s Consumer and Marketplace divisions, leading operations for Nike and Jordan brands.</p>
<p>&#8220;For 32 years, I&#8217;ve had the privilege of working with the best in the industry, helping to shape our company into the magical place it is today,&#8221; Hill said. </p>
<p>&#8220;I&#8217;m eager to reconnect with the many employees and trusted partners I&#8217;ve worked with over the years, and just as excited to build new, impactful relationships that will move us ahead.&#8221;</p>
<p><strong>NKE Price Action:</strong> Nike shares closed Thursday up 0.099%. At publication time, the stock was up 10.01% at $89.09 in extended trading, per <a href="http://pro.benzinga.com">Benzinga Pro</a>.</p>
<p><em>Photo: Shutterstock.</em></p>


Sports

Nike Stock Jumps 9% After The Bell, CEO Set To Retire

WIIM

BATL

Battalion Oil Corp shares are trading higher after the company announced it has amended its merger agreement with Fury Resources for the acquisition of all outstanding shares of Battalion at $7.00 per share in cash.

<p>Investors with a lot of money to spend have taken a bullish stance on <strong>Lowe's Companies</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LOW#NYSE">LOW</a>).</p>
<p>And retail traders should know.</p>
<p>We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.</p>
<p>Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with LOW, it often means somebody knows something is about to happen.</p>
<p>So how do we know what these investors just did? </p>
<p>Today, <a href="https://pro.benzinga.com/?utm_source=insights">Benzinga</a>'s options scanner spotted 21 uncommon options trades for Lowe's Companies.</p>
<p>This isn't normal.</p>
<p>The overall sentiment of these big-money traders is split between 42% bullish and 42%, bearish.</p>
<p>Out of all of the special options we uncovered, 6 are puts, for a total amount of $233,364, and 15 are calls, for a total amount of $1,029,627.</p>
<h3>Projected Price Targets</h3>
<p>Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $200.0 to $280.0 for Lowe's Companies during the past quarter. </p>
<h3>Volume &amp; Open Interest Trends</h3>
<p>In terms of liquidity and interest, the mean open interest for Lowe's Companies options trades today is 1165.5 with a total volume of 3,971.00.</p>
<p>In the following chart, we are able to follow the development of volume and open interest of call and put options for Lowe's Companies's big money trades within a strike price range of $200.0 to $280.0 over the last 30 days.</p>
<h3>Lowe's Companies Call and Put Volume: 30-Day Overview</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1726778848_0.png" alt="Options Call Chart" /></p>
<h3>Significant Options Trades Detected:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th style="text-align: right;"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>LOW</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$7.3</td>
<td>$7.25</td>
<td>$7.3</td>
<td>$280.00</td>
<td>$221.9K</td>
<td>1.5K</td>
<td style="text-align: right;">344</td>
</tr>
<tr>
<td>LOW</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>09/20/24</td>
<td>$11.2</td>
<td>$11.15</td>
<td>$11.15</td>
<td>$250.00</td>
<td>$200.5K</td>
<td>2.0K</td>
<td style="text-align: right;">261</td>
</tr>
<tr>
<td>LOW</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>10/18/24</td>
<td>$5.6</td>
<td>$5.4</td>
<td>$5.4</td>
<td>$260.00</td>
<td>$76.6K</td>
<td>189</td>
<td style="text-align: right;">204</td>
</tr>
<tr>
<td>LOW</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>09/20/24</td>
<td>$11.35</td>
<td>$11.3</td>
<td>$11.3</td>
<td>$250.00</td>
<td>$73.7K</td>
<td>2.0K</td>
<td style="text-align: right;">414</td>
</tr>
<tr>
<td>LOW</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>10/18/24</td>
<td>$14.3</td>
<td>$14.3</td>
<td>$14.3</td>
<td>$250.00</td>
<td>$71.5K</td>
<td>3.0K</td>
<td style="text-align: right;">56</td>
</tr>
</tbody>
</table>
</p>
<h3>About Lowe's Companies</h3>
<p>Lowe's is the second-largest home improvement retailer in the world, operating more than 1,700 stores in the United States, after the 2023 divestiture of its Canadian locations (RONA, Lowe's Canada, Réno-Dépôt, and Dick's Lumber). The firm's stores offer products and services for home decorating, maintenance, repair, and remodeling, with maintenance and repair accounting for two thirds of products sold. Lowe's targets retail do-it-yourself (around 75% of sales) and do-it-for-me customers as well as commercial and professional business clients (around 25% of sales). We estimate Lowe's captures a high-single-digit share of the domestic home improvement market, based on US Census data and management's market size estimates.</p>
<p>After a thorough review of the options trading surrounding Lowe's Companies, we move to examine the company in more detail. This includes an assessment of its current market status and performance.</p>
<h3>Where Is Lowe's Companies Standing Right Now?</h3>
<ul>
<li>With a volume of 2,187,069, the price of LOW is up 1.7% at $261.0. </li>
<li>RSI indicators hint that the underlying stock may be overbought.</li>
<li>Next earnings are expected to be released in 61 days.</li>
</ul>
<h3>Professional Analyst Ratings for Lowe's Companies</h3>
<p>5 market experts have recently issued ratings for this stock, with a consensus target price of $245.6.</p>
<p><strong>Unusual Options Activity Detected: Smart Money on the Move</strong></p>
<p>Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.<br />
&#x2A; An analyst from Telsey Advisory Group persists with their Market Perform rating on Lowe's Companies, maintaining a target price of $230.<br />
&#x2A; Consistent in their evaluation, an analyst from TD Cowen keeps a Hold rating on Lowe's Companies with a target price of $265.<br />
&#x2A; Consistent in their evaluation, an analyst from Gordon Haskett keeps a Hold rating on Lowe's Companies with a target price of $240.<br />
&#x2A; An analyst from Morgan Stanley persists with their Overweight rating on Lowe's Companies, maintaining a target price of $255.<br />
&#x2A; An analyst from RBC Capital has decided to maintain their Sector Perform rating on Lowe's Companies, which currently sits at a price target of $238. </p>
<p>Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.</p>
<p>If you want to stay updated on the latest options trades for Lowe's Companies, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.</p>


Check Out What Whales Are Doing With LOW

<p>Financial giants have made a conspicuous bearish move on Procter &amp; Gamble. Our analysis of options history for Procter &amp; Gamble (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PG#NYSE">PG</a>) revealed 9 unusual trades.</p>
<p>Delving into the details, we found 33% of traders were bullish, while 55% showed bearish tendencies. Out of all the trades we spotted, 2 were puts, with a value of $215,436, and 7 were calls, valued at $548,283.</p>
<h3>Expected Price Movements</h3>
<p>After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $155.0 and $180.0 for Procter &amp; Gamble, spanning the last three months.</p>
<h3>Analyzing Volume &amp; Open Interest</h3>
<p>Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for Procter &amp; Gamble's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Procter &amp; Gamble's whale trades within a strike price range from $155.0 to $180.0 in the last 30 days. </p>
<h3>Procter &amp; Gamble 30-Day Option Volume &amp; Interest Snapshot</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1726778843_0.png" alt="Options Call Chart" /></p>
<h3>Noteworthy Options Activity:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th style="text-align: right;"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>PG</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$4.95</td>
<td>$4.9</td>
<td>$4.95</td>
<td>$180.00</td>
<td>$315.9K</td>
<td>1.4K</td>
<td style="text-align: right;">38</td>
</tr>
<tr>
<td>PG</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>09/20/24</td>
<td>$3.9</td>
<td>$3.7</td>
<td>$3.75</td>
<td>$175.00</td>
<td>$187.5K</td>
<td>2.7K</td>
<td style="text-align: right;">600</td>
</tr>
<tr>
<td>PG</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>10/18/24</td>
<td>$1.95</td>
<td>$1.94</td>
<td>$1.95</td>
<td>$175.00</td>
<td>$55.6K</td>
<td>14.8K</td>
<td style="text-align: right;">611</td>
</tr>
<tr>
<td>PG</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>09/20/24</td>
<td>$0.79</td>
<td>$0.53</td>
<td>$0.79</td>
<td>$172.50</td>
<td>$53.6K</td>
<td>1.4K</td>
<td style="text-align: right;">1</td>
</tr>
<tr>
<td>PG</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>04/17/25</td>
<td>$8.4</td>
<td>$8.1</td>
<td>$8.2</td>
<td>$175.00</td>
<td>$36.8K</td>
<td>129</td>
<td style="text-align: right;">45</td>
</tr>
</tbody>
</table>
</p>
<h3>About Procter &amp; Gamble</h3>
<p>Since its founding in 1837, Procter &amp; Gamble has become one of the world's largest consumer product manufacturers, generating more than $80 billion in annual sales. It operates with a lineup of leading brands, including more than 20 that generate north of $1 billion each in annual global sales, such as Tide laundry detergent, Charmin toilet paper, Pantene shampoo, and Pampers diapers. Sales outside its home turf represent more than half of the firm's consolidated total.</p>
<p>After a thorough review of the options trading surrounding Procter &amp; Gamble, we move to examine the company in more detail. This includes an assessment of its current market status and performance.</p>
<h3>Where Is Procter &amp; Gamble Standing Right Now?</h3>
<ul>
<li>With a trading volume of 8,632,563, the price of PG is down by -1.37%, reaching $171.54.</li>
<li>Current RSI values indicate that the stock is is currently neutral between overbought and oversold.</li>
<li>Next earnings report is scheduled for 27 days from now.</li>
</ul>
<h3>Expert Opinions on Procter &amp; Gamble</h3>
<p>A total of 2 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $188.0.</p>
<p><strong>Unusual Options Activity Detected: Smart Money on the Move</strong></p>
<p>Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.<br />
&#x2A; Maintaining their stance, an analyst from JP Morgan continues to hold a Overweight rating for Procter &amp; Gamble, targeting a price of $186.<br />
&#x2A; In a positive move, an analyst from DZ Bank has upgraded their rating to Buy and adjusted the price target to $190. </p>
<p>Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Procter &amp; Gamble options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.</p>


This Is What Whales Are Betting On Procter & Gamble

Canaccord Genuity analyst William Plovanic maintained a Hold rating on Shockwave Medical (SWAV – Research Report) today and set a price target of $...

Hold Rating Justified for Shockwave Medical Amidst Strong Performance and Pending Johnson & Johnson Acquisition

Shockwave Medical (SWAV) has disclosed a new risk, in the Corporate Activity and Growth category. Shockwave Medical faces significant business risk...

Shockwave Medical's High Stakes: The Cost of a Collapsed Johnson & Johnson Merger

Analyst Larry Biegelsen from Wells Fargo maintained a Hold rating on Shockwave Medical (SWAV – Research Report) and increased the price target to $...

Maintaining Hold: Shockwave Medical's Solid Performance Tempered by Market Valuation

Shockwave Medical: A Look Into Q1 Financials And Value To Johnson & Johnson Investors

Shockwave Medical gains after HSR waiting period for sale to J&J expires

Harding Loevner Global Small Companies Equity Composite Q1 2024 Report

Sarepta Therapeutics to replace Shockwave Medical in the S&P MidCap 400

J&J completes acquisition of cardiac device maker Shockwave

An update from Shockwave Medical (SWAV) is now available. The recent merger of a company has triggered significant changes for note holders and sto...

Shockwave Medical's Structural Shift Following Major Merger

<p><a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a></p>
<p>The financial media does its best to keep you informed about what&rsquo;s happening in the market. However, this has the effect of giving significant attention to a handful of leaders or laggards. That creates an opportunity for investors who have the patience to look for must-own overlooked stocks. &nbsp;</p>



<p>Overlooked stocks are not necessarily underperforming the market. In some cases, these stocks simply are slow and steady at a time when investors want to find the newest and brightest shiny object. &nbsp;</p>



<p>However, not every shiny object is <strong>Nvidia</strong> (NASDAQ:<span><a href="https://investorplace.com/stock-quotes/nvda-stock-quote/"><strong>NVDA</strong></a></span>). And the more light that starts shining on a high-profile stock, the more likely it is that the stock could move sharply lower on the slightest bit of bad news. &nbsp;</p>



<p>Another common misconception about overlooked stocks is that they come with a cheap price tag. This is also not necessarily true. In fact, sometimes a stock gets overlooked because it seems too expensive for retail investors. &nbsp;</p>



<p>In the end, must-buy overlooked stocks come down to value more than price. Because value always wins out over time. Here are seven stocks that investors are overlooking now but may shift back towards when market conditions change. &nbsp;</p>



<h2>AbbVie (ABBV)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2023/01/abbv1600-300x169.png" alt="Closeup of AbbVie (ABBV) building corporate office, an American biopharmaceutical company with its headquarters in Lake Bluff, Illinois, USA"><div>Source: Valeriya Zankovych / Shutterstock.com</div></div><p><strong>AbbVie</strong> (NYSE:<span><a href="https://investorplace.com/stock-quotes/abbv-stock-quote/"><strong>ABBV</strong></a></span>) is up 13.4% in the last 12 months but is down 11% in the last three months. The biopharmaceutical giant is being overlooked for a couple of reasons. First, with a price-to-earnings (P/E) ratio of around 40x, it&rsquo;s hardly a cheap stock. Second, investors want to see how the company&rsquo;s revenue and earnings will hold up now that its flagship Humira drug faces biosimilar competition in the U.S. and Europe.&nbsp;</p>



<p>When looking at the P/E ratio it&rsquo;s helpful to note that AbbVie has a forward P/E of around 13x earnings. That&rsquo;s much more attractive. &nbsp;</p>



<p>Then there&rsquo;s the Humira question. There&rsquo;s no doubt that the company is seeing pressure from competitors. In its April earnings report, AbbVie reported a <a href="https://investors.abbvie.com/static-files/af510304-0bc1-4781-9090-b6c4a9be5edb" target="_blank">39% decline in Humira revenue</a> in the United States. &nbsp;</p>



<p>However, AbbVie also <a href="https://investorplace.com/2024/05/7-safe-haven-stocks-to-weather-any-storm/" target="_blank">reported strong growth from two of its newer drugs</a>: Skyrizi and Rinvoq. These drugs are integral to the company&rsquo;s plans for replacing the lost Humira revenue. AbbVie also has a deep pipeline with <a href="https://www.abbvie.com/science/pipeline.html" target="_blank">50 drugs in mid- and late-stage development</a>. &nbsp;</p>



<p>Since the company&rsquo;s earnings report, analysts have assigned a <a href="https://www.tradingview.com/chart/aMepJfAr/?symbol=NYSE%3AABBV&amp;utm_source=www.marketbeat.com&amp;utm_medium=widget&amp;utm_campaign=chart-logo&amp;utm_term=NYSE%3AABBV" target="_blank">consensus price target of $182.90</a>. That&rsquo;s a 17% gain. Plus, AbbVie is a dividend king that not only has increased its dividend for 52 consecutive years, but the stock has an attractive yield of 3.98%. &nbsp;</p>



<h2>Johnson &amp; Johnson (JNJ)&nbsp;</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2019/10/jnj1600b-300x169.jpg" alt="jnj healthcare stocks"><div>Source: Raihana Asral / Shutterstock.com</div></div><p><strong>Johnson &amp; Johnson </strong>(NYSE:<span><a href="https://investorplace.com/stock-quotes/jnj-stock-quote/"><strong>JNJ</strong></a></span>) is another biopharmaceutical company on this list of must-own overlooked stocks. Unlike AbbVie, investors can&rsquo;t say that JNJ stock is expensive. It has a current P/E of 9x and a forward P/E of 13x. &nbsp;</p>



<p>Nevertheless, valuation remains an issue as investors are trying to price JNJ stock without its consumer products division that it spun off as <strong>Kenvue</strong> (NYSE:<span><a href="https://investorplace.com/stock-quotes/kvue-stock-quote/"><strong>KVUE</strong></a></span>) in 2023. The company is also working to resolve its long-running lawsuits stemming from its talc powder. In January, AbbVie announced it was moving forward on a <a href="https://www.cnn.com/2024/05/01/business/j-and-j-talc-cancer-lawsuits-settlement/index.html" target="_blank">$6.475 billion proposed settlement</a> of tens of thousands of lawsuits. However, there <a href="https://www.foxbusiness.com/markets/johnson-johnson-sued-cancer-victims-fraudulent-bankruptcies" target="_blank">may still be some work to do</a>. &nbsp;</p>



<p>The past shouldn&rsquo;t be overlooked. But the bullish case for JNJ stock is about the future. And its acquisition of<strong> Shockwave Medical</strong> (NASDAQ:<span><a href="https://investorplace.com/stock-quotes/swav-stock-quote/"><strong>SWAV</strong></a></span>) is a key part of that. The <a href="https://investorplace.com/2024/04/wall-street-favorites-3-dividend-stocks-with-strong-buy-ratings-for-april-2024/" target="_blank">$13.1 billion acquisition</a> will bring Shockwave&rsquo;s first-to-market intravascular lithotripsy technology (ILT) under Johnson &amp; Johnson&rsquo;s MedTech division. &nbsp;</p>



<p>Once this acquisition becomes accretive to JNJ&rsquo;s top and bottom lines, JNJ stock will look extremely attractive for more than just its dividend which has a 3.48% yield. And with 62 years of consecutive dividend increases, Johnson &amp; Johnson is another dividend king on this list. &nbsp;</p>



<h2>PepsiCo (PEP)&nbsp;</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/02/pep-pepsico-1600-300x169.png" alt="Pepsi (PEP) Factory in Samara, Russia. Pepsi logo on a blue warehouse."><div>Source: FotograFFF / Shutterstock</div></div><p><strong>PepsiCo</strong> (NASDAQ:<span><a href="https://investorplace.com/stock-quotes/pep-stock-quote/"><strong>PEP</strong></a></span>) is the third and final dividend king on this list of must-own overlooked stocks. The consumer staples giant has been largely able to <a href="https://investorplace.com/2024/05/7-reliable-blue-chip-stocks-that-cannot-miss/" target="_blank">pass along some of its higher producer costs</a>. But growth is slowing, and there is concern that consumer spending is slowing as well. Just as Pepsi benefits from both beverage and snack food sales when consumers trade up, it can suffer when consumers trade down. &nbsp;</p>



<p>This pessimism is reflected in PEP stock, which is essentially flat in 2024 and down about 5% in the last 12 months. That&rsquo;s not a massive dip to buy, but the stock is trading at around $170 which has served as a level of support and resistance in the last two years. &nbsp;</p>



<p>History shows that buying dips, no matter how small, in PEP stock is a solid strategy. One reason has to do with the company&rsquo;s previously mentioned dividend which yields 2.96% as of this writing and has been growing for 53 consecutive years. &nbsp;</p>



<h2>Sofi Technologies (SOFI)&nbsp;</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2023/10/sofi1600-1-300x169.png" alt="SoFi Technologies, Inc logo with stock market chart background. is an American online personal finance company and online bank."><div>Source: Poetra.RH / Shutterstock.com</div></div><p><strong>Sofi Technologies</strong> (NASDAQ:<span><a href="https://investorplace.com/stock-quotes/sofi-stock-quote/"><strong>SOFI</strong></a></span>) falls under the category of &ldquo;yeah, but&rdquo; stocks. Okay, I invented the category, but the premise is this. Sofi has largely delivered what it has said it would do. It was an online lender primarily known for providing student loans. Yeah, but it wasn&rsquo;t a real bank. Then it got its&nbsp;bank charter. Yeah, but it wasn&rsquo;t profitable. Now it&rsquo;s delivered two straight quarters of positive adjusted EPS. &nbsp;</p>



<p>Still the stock can&rsquo;t seem to get out of the snares of short sellers. A considerable 18% of the SOFI stock float is being shorted. And with only 38% of the shares owned by institutions, it&rsquo;s been a tough hold. &nbsp;</p>



<p>SOFI stock is bouncing around $6.80. The good news is this has been a solid level of support. The bad news is that the company continues to revisit this level. The key will come from future growth, and in that regard being an internet-only bank <a href="https://investorplace.com/2024/05/secret-stocks-with-sizzle-3-low-profile-picks-packing-high-profit-potential/" target="_blank">lowers the company&rsquo;s customer acquisition costs</a>. &nbsp;</p>



<h2>Pfizer (PFE)&nbsp;</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2019/08/pfe-stock-2-300x169.jpg" alt="blue Pfizer logo on the windows of a corporate building PFR stock"><div>Source: photobyphm / Shutterstock.com</div></div><p><strong>Pfizer</strong> (NYSE:<span><a href="https://investorplace.com/stock-quotes/pfe-stock-quote/"><strong>PFE</strong></a></span>) is down 24% in the last 12 months and nearly 50% since its peak of near $60 in November 2021. The rise and fall of PFE stock was entirely predictable. The company was first-to-market with a vaccine for Covid-19. And it enjoyed the benefits of that position in its revenue and earnings. &nbsp;</p>



<p>However, as demand for the company&rsquo;s Covid-19 products wanes, so does the stock which is facing difficult comparisons. That said, Pfizer is being overlooked for many reasons, some of which have nothing to do with the intrinsic value of the stock. &nbsp;</p>



<p>That&rsquo;s part of the buying thesis. The mRNA technology that was used in the Covid-19 vaccine is already being used to develop other vaccines. The company is also making strides in oncology as well as areas such as <a href="https://www.pfizer.com/science" target="_blank">gene therapy and precision medicine</a>. And Pfizer has the balance sheet to get these products to the finish line whether it goes alone or through acquisition. &nbsp;</p>



<p>Analysts have a consensus Hold rating on PFE stock, but the price target is 37% higher. That&rsquo;s a discrepancy that makes it tempting to start a position. That&rsquo;s particularly true because, while you wait, you&rsquo;re getting a dividend with a 5.97% yield. &nbsp;</p>



<h2>Enphase Energy (ENPH)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2023/07/enph1600-300x169.png" alt="Smartphone with logo of American company company Enphase Energy Inc. (ENPH) on screen in front of business website. Focus on left of phone display. Unmodified photo."><div>Source: T. Schneider / Shutterstock.com</div></div><p><a href="https://investorplace.com/industries/energy/renewable-energy/solar/">Solar stocks</a> have been hit and miss for investors. There are stocks like <strong>First Solar</strong> (NASDAQ:<span><a href="https://investorplace.com/stock-quotes/fslr-stock-quote/"><strong>FSLR</strong></a></span>) that are ripping higher. But a company like <strong>Enphase Energy </strong>(NYSE:<span><a href="https://investorplace.com/stock-quotes/enph-stock-quote/"><strong>ENPH</strong></a></span>), which was a darling of the solar sector in 2021 and 2022 has been having a rough time. &nbsp;</p>



<p>The company serves a largely residential audience and has been faced with declining revenue which has caused earnings to turn negative. Simply put, Enphase desperately needs a rate cut that will stimulate home buying and consumer investment in solar technology. &nbsp;</p>



<p>That may have to wait until 2025, but here&rsquo;s why you may want to put Enphase on a list of must-own overlooked stocks. Analysts have a consensus price target of $127.12. That&rsquo;s 2% lower than the price as of this writing. But <a href="https://www.tradingview.com/chart/aMepJfAr/?symbol=NASDAQ%3AENPH&amp;utm_source=www.marketbeat.com&amp;utm_medium=widget&amp;utm_campaign=chart-logo&amp;utm_term=NASDAQ%3AENPH" target="_blank">22 out of 42 analysts give ENPH stock a Strong Buy or Buy rating</a>. That suggests there may be a bigger dip coming for ENPH stock, but that would be a good time to take a position. &nbsp;</p>



<h2>Norwegian Cruise Line (NCLH)&nbsp;</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/06/nclh-1600-1-300x169.jpg" alt="Norwegian Cruise Line ship arriving at a port. NCLH stock."><div>Source: Ian_Stewart / Shutterstock</div></div><p>Cruise line stocks were a no-brainer long-term buy in 2020 and 2021. The industry was decimated by the global pandemic. But the smart money knew the industry would come back as it has. However, <strong>Norwegian Cruise Line</strong> (NYSE:<span><a href="https://investorplace.com/stock-quotes/nclh-stock-quote/"><strong>NCLH</strong></a></span>) has been largely ignored. Investors have a high bar and little patience. All it took was a slight miss on the top line to spook investors and turn NCLH stock negative for the year.&nbsp;</p>



<p>But this could be the stock&rsquo;s time to shine. Analysts are lining up behind Norwegian on expectations of earnings growth that could reach 30%, not just this year but for each of the next three years. That would help the cruise line retire a significant chunk of the $14 billion net debt load it&rsquo;s still carrying. &nbsp;</p>



<p>To deliver on those projections, it seems like the company is counting on younger travelers. The company recently cited millennial and Gen-Z passengers as being its <a href="https://www.nbclosangeles.com/news/business/money-report/norwegian-cruise-line-ceo-says-millennials-and-gen-z-are-the-fastest-growing-segment/3416765/" target="_blank">fastest growing demographic</a>. That could be a double-edged sword if the economy worsens. However, over time these are the passengers that will have growing income to spend on experiences. &nbsp;</p>



<p><em>On the date of publication, Chris Markoch did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the </em>InvestorPlace.com<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank"><em> </em>Publishing Guidelines.</a>&nbsp;</p>
<div><p>Chris Markoch is a freelance financial copywriter who has been covering the market for over five years. He has been writing for InvestorPlace since 2019.</p></div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT802110">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	
<p>The post <a href="https://investorplace.com/2024/06/7-must-own-overlooked-stocks-that-can-work-in-any-portfolio/">7 Overlooked Stocks That Belong in Every Portfolio </a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.</p>

7 Overlooked Stocks That Belong in Every Portfolio

ABBV

ATLCY

ATLFF

ATLKY

ATLPF

CYBR

DAVA

ENPH

FSLR

KVUE

MSSMY

MSUXF

NEMKY

NEMTF

NVDA

PFFVF

RBSFY

RUBSF

SOFI

YUGVF

Press Releases

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CTLT, HRT, SWAV, MODN

Legal

Kuehn Law Encourages IP, SWAV, NX, and UNIT Investors to Contact Law Firm

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates UNIT, SWAV, IP, NX

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AGBA, HIBB, SWAV

Shockwave Medical Reports First Quarter 2024 Financial Results

Kuehn Law Encourages SWAV, ALE, PRFT, and LSAK Investors to Contact Law Firm

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ALE, PRFT, SWAV

SHOCKWAVE MEDICAL INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Shockwave Medical, Inc. - SWAV

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Comments

SHOCKWAVE MED INC

SHOCKWAVE MED INC (SWAV) Forecast

SHOCKWAVE MED INC (NASDAQ:SWAV) Stock, Quote.Headers.trade-ideas